Koers AXIM Biotechnologies, Inc. Other OTC
Aandelen
AXIM
US05463V1008
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 8,88K 8,33K | Omzet 2023 | 39,52K 37,08K | Marktkapitalisatie | 4,52 mln. 4,24 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -6 mln. -5,63 mln. | Nettowinst (verlies) 2023 | -8 mln. -7,51 mln. | EV/omzet 2022 | 1.218 x |
Nettoschuld 2022 | 5,64 mln. 5,3 mln. | Nettoschuld 2023 | 5,74 mln. 5,38 mln. | EV/omzet 2023 | 259 x |
K/w-verhouding 2022 |
-0,69
x | K/w-verhouding 2023 |
-0,48
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 71,61% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 29-06-16 |
Kurt Phinney
COO | Chief Operating Officer | - | 23-05-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 18-05-17 |
Director/Board Member | 76 | 18-05-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,86 mld. | |
+10,92% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,23% | 25,15 mld. | |
-24,79% | 18,63 mld. | |
+26,69% | 12,37 mld. | |
-3,13% | 11,92 mld. | |
+6,57% | 11,21 mld. |